Aurinia Pharmaceuticals (AUPH) Short-term Investments (2017 - 2026)

Aurinia Pharmaceuticals' Short-term Investments history runs 9 years deep, the most recent figure standing at $337.8 million for Q1 2026.

• Quarterly Short-term Investments rose 37.04% year-over-year to $337.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $337.8 million (up 37.04% YoY) and the FY2025 annual result came in at $317.8 million, up 15.54% from the prior year.
• Short-term Investments was $337.8 million for Q1 2026 at Aurinia Pharmaceuticals, up from $317.8 million in the prior quarter.
• Across five years, Short-term Investments topped out at $337.8 million in Q1 2026 and bottomed at $240.1 million in Q2 2022.
• A 5-year average of $284.0 million and a median of $286.2 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 49.3% — and 2025, when it slipped 11.76%.
• Aurinia Pharmaceuticals' Short-term Investments stood at $295.2 million in 2022, then advanced by 2.17% to $301.6 million in 2023, then retreated by 8.81% to $275.0 million in 2024, then gained by 15.54% to $317.8 million in 2025, then gained by 6.29% to $337.8 million in 2026.
• Business Quant data shows AUPH's Short-term Investments at $337.8 million in Q1 2026, $317.8 million in Q4 2025, and $278.6 million in Q3 2025.